Clinical Trials

We are currently advancing several drugs through clinical trials, including VB-201, which targets inflammatory conditions such as psoriasis and VB-111, which holds promise for the treatment of cancer. For detailed information about our clinical trials, please visit www.clinicaltrials.gov and search under VB-201 or VB-111 for a list of ongoing trials.

Ongoing Trial - Psoriasis

Our lead compound, VB-201, has significant potential to treat inflammation in chronic diseases such as psoriasis, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis and atherosclerosis.

 

  • Preclinical Insights - In extensive preclinical studies, VB-201 demonstrated efficacy in multiple immune-inflammatory conditions, including psoriasis. VB-201 showed a unique disease-modifying mechanism for attenuating cell-mediated, pro-inflammatory processes. The favorable safety and efficacy profile observed in preclinical model paved the way for a U.S. IND and Phase 1 clinical trials.

 

  • Phase 1 Clinical Trials Complete – VB-201 successfully completed four Phase 1 clinical trials involving 120 healthy volunteers under a U.S. IND. This includes single and multiple-dose studies in which safety and tolerability were similar to placebo.

 

  • Phase 2 Clinical Trials Underway – We have initiated a multi-center Phase 2 efficacy and safety study in the U.S., Germany and Israel evaluating VB-201 for the treatment of patients with psoriasis. VB-201 is a first-in-class, orally administered immune-response modifier that is expected to reduce inflammation in a broad range of diseases.

    The Phase 2 double-blind, randomized, dose-ranging, placebo-controlled study will enroll approximately 180 patients with moderate to severe psoriasis. Patients will receive VB-201 or placebo once-daily for 12 weeks. The primary endpoint in the study is improvement in the Psoriasis Area and Severity Index (PASI 75) at week 12. The study will be conducted at multiple centers in the United States, Germany and Israel. Detailed information on the clinical trial can be found at www.clinicaltrials.gov.

Upcoming Trial - Thyroid Cancer

VB-111 will be tested in thyroid cancer patients in a Phase 2 study in 2010.

Physician Inquiries

If you are interested in learning more about VBL’s investigational new drugs and clinical trials, please contact us via email at: naama@vblrx.com